Dresden, Germany
Dresden, Germany

The Technische Universität Dresden is the largest institute of higher education in the city of Dresden, the largest university in Saxony and one of the 10 largest universities in Germany with 37,134 students as of 2013. The name Technische Universität Dresden has only been used since 1961; the history of the university, however, goes back nearly 200 years to 1828. This makes it one of the oldest colleges of technology in Germany, and one of the country’s oldest universities, which in German today refers to institutes of higher education which cover the entire curriculum. The university is member of TU9, a consortium of the nine leading German Institutes of Technology. The university is one of the eleven German universities which succeeded in the Excellence Initiative in 2012, thus getting the title of a "University of Excellence". The TU Dresden succeeded in all three rounds of the German Universities Excellence Initiative . Wikipedia.

SEARCH FILTERS
Time filter
Source Type

The present invention relates to a method of reproducing at least one single-walled carbon nanotube (3) having predefined electronic properties or a plurality of single-walled carbon nanotube (3) having the same electronic properties. A dispersion (2) is produced for this purpose and carbon nanotubes (3) contained in the dispersion are processed into fragments (6) by energy input. These fragments (6) are applied to and oriented on a carrier (7). The fragments (6) are subsequently extended by chemical vapor deposition and the originally present carbon nanotubes (3) are thus reproduced.


Patent
TU Dresden | Date: 2015-07-28

The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.


The present invention relates to a method for the sensitive identification of high-affinity complexes made of two ligands (2, 3, 4, 5, 6, 7) and one receptor (1). A large number of different ligands (2, 3, 4, 5, 6, 7) of a chemical library are hereby contacted with at least one receptor (1) in a solution. The ligands of the library have a single-strand DNA (8, 9) or RNA with a base length of 2 to 10 bases or alternatively more than 10 bases. In addition, the solution is incubated for a specific period of time and complexes made of two ligands (2, 3, 4, 5, 6, 7) and one receptor (1) are identified.


The invention relates to a method for the Raman spectroscopic, in ovo sex determination of fertilised and hatched birds eggs (1), wherein the embryo, including the extra-embryonic structures, can move in the egg, and is not yet attached to the shell at the time of measuring. In addition, the following steps are carried out: monitoring the time course of the hatched egg until forming at least one recognisable blood vessel (21); creating a hole (2) in the shell in the region near to the attached bloody vessel, using a hole-generating unit; finding the blood vessel forming in the egg, using a vision system (19, 13) and a coaxial or lateral illumination with light (10a) in the visible wavelength range; positioning at least one blood vessel in the laser focus of a laser source (3), either by moving the egg or moving a lens (6) of a device (5) for introducing the laser light (3a), and detecting the Raman scattered radiation (7); registering the Raman scattered radiation of the irradiated blood vessel using the device for introducing the laser light, and for detecting the Raman scattered radiation, wherein, during the measuring process, a movement of the blood vessel out of the focus can be avoided by tracking using the vision system; evaluating the Raman scattered radiation in an evaluation unit; determining and displaying the sex of the embryo in the birds egg.


A method for generating random numbers on multiprocessor systems and a multiprocessor system for generating true random numbers, using the method, generate truly random numbers with high entropy in a multiprocessor system with little additional effort to chip area and power dissipation. The method includes the steps of: measuring a phase error signal of a clock generator circuit of a first and a second processing unit respectively, forwarding the phase error signal of the respective clock generator circuit of the first and second processing unit to a true random network, combining the phase error signal of the clock generator circuit of the first processing unit and the phase error signal of the clock generator circuit of the second processing unit in the true random network to random bit streams, picking-up a random bit stream of the true random network, passing the respective random bit stream back to a random generator of the respective processing unit for outputting true random.


Grant
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016

Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses ICT to integrate neuroscience data from around the world, to develop a unified multi-level understanding of the brain and diseases, and ultimately to emulate its computational capabilities. The goal is to catalyze a global collaborative effort. During the HBPs first Specific Grant Agreement (SGA1), the HBP Core Project will outline the basis for building and operating a tightly integrated Research Infrastructure, providing HBP researchers and the scientific Community with unique resources and capabilities. Partnering Projects will enable independent research groups to expand the capabilities of the HBP Platforms, in order to use them to address otherwise intractable problems in neuroscience, computing and medicine in the future. In addition, collaborations with other national, European and international initiatives will create synergies, maximizing returns on research investment. SGA1 covers the detailed steps that will be taken to move the HBP closer to achieving its ambitious Flagship Objectives.


IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA). Palliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (10 sites, WHO 0-1: oligo\) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC. IMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.


Grant
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016

This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-11-2016-2017 | Award Amount: 7.60M | Year: 2017

PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputation (below the knee or higher) and cardiovascular death (1-year amputation-free survival <60%; 10-year mortality 70%). CLI has a strong social impact and its incidence is rising worldwide, including in Europe. The prevalence of CLI in the population aged 6090 years is estimated as 1% (0.51.2%) with male to female ratio around 3:1. We will evaluate the efficacy, tolerability and safety of multiple intramuscular injections of HLA-unmatched allogeneic PLX-PAD for the treatment of CLI patients who are unsuitable for revascularization, in a randomized, double-blind, multicentre, placebo-controlled, parallel group phase II study. The European Medicine Agency (EMA) accepted PLX-PAD as pilot project for the new Adaptive Pathways to Patients to force timely access for patients to the new therapeutic option. The PACE consortium will go beyond the traditional clinical trial endpoints of safety and efficacy, by state-of-the-art characterizing molecular and functional signature of the PLX-PAD product(s), in depth investigating mechanisms-of-action of PLX-PAD therapy, and exploring biomarkers for understanding response/non-response in particular patients (stratification and therapy response markers). PACE partners are world-leading experts in scalable, clinical grade 3D-cell manufacturing approved by authorities, preclinical and clinical cell therapy, and biomarker analyses with well recognized expertise in designing and performing clinical trials, including those with Advanced Therapy Medicinal Products (ATMPs) integrated with in-patient biomarker and mechanistic side-studies.

Loading TU Dresden collaborators
Loading TU Dresden collaborators